Clinical Trial Update: A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for alectinib in RET-rearranged non-small cell lung cancer and RET-mutated thyroid cancer; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-11-25